Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05563766 · ClinicalTrials.gov registry record · Phase 2
A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer
A Phase 2 study of Esophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma, sponsored by VA Office of Research and Development.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 78
- Enrollment target
- 7
- Study locations
NCT05563766 is a Phase 2 study of Esophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma that is actively recruiting participants, run by VA Office of Research and Development. The registered enrollment target is 78 participants, below the 307-participant average among 43 other Esophageal Adenocarcinoma trials with a reported enrollment target (75% lower). The trial reports 7 study locations across 6 states.
The verdict
NCT05563766, a Phase 2 study of Esophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma, is actively recruiting participants, sponsored by VA Office of Research and Development.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 78 participants
- Enrollment target
- 7
- Study locations
Study Summary
Esophageal cancer, which has a low 5-year overall survival rate (\<20%) is increasing in incidence. Previous studies have shown that Hedgehog, AKT, and angiogenic signaling pathways are activated in a significant number of esophageal cancers. Itraconazole, a widely used anti-fungal medication, effectively inhibits these pathways. In this multi-site phase II trial, the investigators will evaluate the effect of itraconazole as a neoadjuvant therapy added to standard of care chemoradiation and surgery in the the treatment of locoregional esophageal and gastroesophageal junction cancers.
Conditions Studied
Interventions
- DRUG Itraconazole
Study Locations (7)
Texas
- VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX - Dallas
- Michael E. DeBakey VA Medical Center, Houston, TX - Houston
California
- VA Palo Alto Health Care System, Palo Alto, CA - Palo Alto
Michigan
- VA Ann Arbor Healthcare System, Ann Arbor, MI - Ann Arbor
North Carolina
- Durham VA Medical Center, Durham, NC - Durham
Oregon
- VA Portland Health Care System, Portland, OR - Portland
Washington
- VA Puget Sound Health Care System Seattle Division, Seattle, WA - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2024-10-01 |
| Est. Completion | 2029-06-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05563766
The ClinicalTrials.gov registry entry for NCT05563766 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 307-participant average among 43 other Esophageal Adenocarcinoma trials with a reported enrollment target (75% lower). The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Esophageal Adenocarcinoma appearing as the primary indexed condition, and to 1 intervention - of which Itraconazole is the first listed.
NCT05563766 reports 7 study locations spanning 6 distinct geographic areas - top geographies include Texas, California, Michigan.
Frequently Asked Questions
What is clinical trial NCT05563766 about?
NCT05563766 is a clinical study titled "A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer". Esophageal cancer, which has a low 5-year overall survival rate (\<20%) is increasing in incidence. Previous studies have shown that Hedgehog, AKT, and angiogenic signaling pathways are activated in a significant number of esophageal cancers. Itraconazole, a widely used anti-fungal medication, effec...
What is the current status of trial NCT05563766?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 78 participants. The study started on 2024-10-01. Estimated completion is 2029-06-15.
What conditions does trial NCT05563766 study?
This clinical trial studies the following conditions: Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Gastroesophageal Junction Carcinoma.
What interventions are being tested in trial NCT05563766?
The interventions under investigation include: Itraconazole (DRUG).
Who is sponsoring clinical trial NCT05563766?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05563766 being conducted?
This trial has 7 study locations across California, Michigan, North Carolina, Oregon, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Esophageal Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
RECRUITING · Phase 2
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
RECRUITING · Phase 2
-
Propranolol With Standard Chemoradiation for Esophageal Adenocarcinoma
RECRUITING · Phase 2
-
Obeticholic Acid for Prevention in Barrett's Esophagus
RECRUITING · Phase 2
-
Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels
RECRUITING · Phase 2
Explore more on PlainTrial
Esophageal Adenocarcinoma
All registered trials for this condition
Esophageal Squamous Cell Carcinoma
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.